Nicotinic Receptor Augmentation of SSRI Antidepressants

NCT00319319 ↗

Phase 2 Completed 60 enrolled Yale University Donaghue Medical Research Foundation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial.

Timeline

Start: 2003-01
Primary completion: —
Completion: 2007-01

Outcome

Met primary endpoint

paper There was a significant reduction in 17-item Hamilton Depression Rating Scale scores in the MEC versus PLO groups PMID 18480694 ↗

paper F1,19 = 6.47, P < 0.05 PMID 18480694 ↗

Publications

George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol. 2008 Jun;28(3):340-4. doi: 10.1097/JCP.0b013e318172b49e.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mecamylamine	Small molecule	5 mg	Oral